Metraipolis › archive › dc_0314becbeefb

Tenofovir Alafenamide Versus Entecavir as Switch Therapy After Tenofovir Disoproxil Fumarate in Patients with Chronic Hepatitis B — Europe PMC PMID:42652661

Source: Europe PMC (en)
Original: https://europepmc.org/article/MED/42652661
DOI: 10.3390/jcm15166257
License (as archived): solo-consultazione
Archived: 2026-10-16T15:55:52.052Z
SHA-256 of the archived text: ce4291809b880ffc911b4094c95d8e84a9b908ce9b4c26909f9f0f7f1a56c4d3
Stable URL of this page: https://metraipolis.com/documento/dc_0314becbeefb

How to cite

Tenofovir Alafenamide Versus Entecavir as Switch Therapy After Tenofovir Disoproxil Fumarate in Patients with Chronic Hepatitis B — Europe PMC PMID:42652661 — Europe PMC (en), https://europepmc.org/article/MED/42652661 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_0314becbeefb (Metraipolis archive dc_0314becbeefb, sha256 ce4291809b880ffc911b4094c95d8e84a9b908ce9b4c26909f9f0f7f1a56c4d3)

BibTeX

@misc{dc0314becbeefb,
  title = {Tenofovir Alafenamide Versus Entecavir as Switch Therapy After Tenofovir Disoproxil Fumarate in Patients with Chronic Hepatitis B — Europe PMC PMID:42652661},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/42652661},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_0314becbeefb; sha256 ce4291809b880ffc911b4094c95d8e84a9b908ce9b4c26909f9f0f7f1a56c4d3},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42652661. Agents can read the archived copy with the MCP tool read_document.